OSE Immunotherapeutics Archives

News and Trends 25 Mar 2016

Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle and, of course the Eiffel Tower, the Louvre and le baguette, Paris is also the home of OSE Pharma, our Biotech of the Week. City: Paris (France) Founded: 2012 Employees: N/A Financial Data: €24.3M total raised (as of […]

March 25, 2016 - 2 minutesmins - By Joachim Eeckhout

tedopi nsclc lung cancer ose pharma atlante

News and Trends 8 Feb 2016

French Biotech Launches Phase III Global Trial for Lung Cancer Drug

OSE Pharma (France) has initiated the US phase III trial, Atalante 1. This global, pivotal trial will evaluate Tedopi, the company’s lead product, for advanced non-small cell lung cancer (NSCLC). The phase III study was initiated in Europe in early 2016, so the screening of eligible patients diagnosed with non-small cell lung cancer is now actively ongoing in […]

February 8, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Jan 2016

3 French Bioentrepreneurs are Awarded for Being Stubborn

Building a company is extremely difficult and obstination is sometimes needed to reach success. The organisation, France Biotech, has given a price to the founder of Innate-Pharma, OSE Pharma and Effimune for their respective success. Why? From left to right, Hervé Brailly, CEO & Founder of Innate-Pharma, Denis Lucquin, Managing Director of Sofinnova Partners, Maryvonne Hiance, […]

January 7, 2016 - 3 minutesmins - By Philip Hemme

msd avelumab pdl1 immunooncology pfizer etinostat

News and Trends 5 Jan 2016

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms how PD-L1 receptor is seen as the current breakthrough therapeutic target in Immuno-Oncology. Program-Death ligand 1 (PD-L1) is already a common target for mAbs in immuno-oncology. If expressed on the tumor cells, this enables the […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

France’s leading Female Bio-entrepreneur joins board of Abivax

Dominique Costantini is one of France’s leading biotech figures, with over 20 years experience on boards, partnerships and business backing in some of the biotech industries leading brands. With a medical background specializing in immunology (from Paris V University), Costantini co-founded oncology focused Onxeo in 1997. Formerly known as BioAlliance Pharma, this biotech went public […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Aug 2015

Paris is Europe’s biggest Biocluster, but nobody knows it …

Paris is well-known for being the most beautiful city in the world. But did you also know that it concentrates most of the French Biotech industry and is Europe’s biggest biocluster? If not, why didn’t you know? The Eiffel Tower, the Louvre, Notre Dame and so many other monuments makes Paris outstanding and unique. But Paris […]

August 19, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 27 Mar 2015

OSE Pharma raised €21.1 Million

OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for shares, the board of OSE Pharma has increased the price of the capital to €10.80 per share, corresponding to the top of the indicative price range of the offer. On this basis, the market capitalization […]

March 27, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 10 Mar 2015

The Promising Company OSE Pharma launches an IPO

Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. The company announced the launch of its Initial Public Offering (IPO) on Euronext’s regulated […]

March 10, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us